ReviewThe Medical clinics of North America2017
Cervical Cancer Screening.
Review in The Medical clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- The Impact of the COVID-19 Pandemic on Breast and Cervical Cancer Screening: A Systematic Review.In vivo (Athens, Greece)Pooled it
- Enhancing efficiency and improving turnaround time: real-world impact of the Genius Digital Diagnostics System implementation.American journal of clinical pathology · 2026Article
- Structural Racism in Cervical Cancer Care and Survival Outcomes: A Systematic Review of Inequities and Barriers.Current epidemiology reports · 2025Review
- The E3 ubiquitin ligase RNF6 facilitates the progression of cervical cancer by inhibiting the Hippo/Yap pathway.Cell division · 2024Article
- Determinants of cervical cancer screening among women of childbearing age in four sub-Saharan African countries: insights from large population surveys.BMC cancer · 2024Article
- Single-cell RNA sequencing of cervical exfoliated cells reveals potential biomarkers and cellular pathogenesis in cervical carcinogenesis.Cell death & disease · 2024Article
- Global, regional, and national quality of care index of cervical and ovarian cancer: a systematic analysis for the global burden of disease study 1990-2019.BMC women's health · 2024Article
- Prevalence of High-Risk Human Papillomavirus Genotypes among Young Women in Puerto Rico; a retrospective longitudinal study.Research square · 2023Article
- Article
- Article
- Prevention of Cervical Cancer in Low-Resource African Settings.Obstetrics and gynecology clinics of North America · 2022Review
- Review
- Cervix Type and Cervical Cancer Classification System Using Deep Learning Techniques.Medical devices (Auckland, N.Z.) · 2022Article
- Cervical Cancer Screening Among Immigrant and Refugee Women: Scoping-Review and Directions for Future Research.Journal of immigrant and minority health · 2020Article
- Efficacy of paclitaxel, carboplatin, and bevacizumab for cervical cancer: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- The value of cytokine levels in triage and risk prediction for women with persistent high-risk human papilloma virus infection of the cervix.Infectious agents and cancer · 2019Article
- Awareness of surgical smoke hazards and enhancement of surgical smoke prevention among the gynecologists.Journal of Cancer · 2019Review
- Decreased expression of aquaporin 1 correlates with clinicopathological features of patients with cervical cancer.OncoTargets and therapy · 2019Article
- PBX3 is associated with proliferation and poor prognosis in patients with cervical cancer.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Cervical cancer screening in the United States has accompanied profound decreases in cancer incidence and mortality over the last half century. Two screening strategies are currently endorsed by US-based guideline groups: (1) triennial cytology for women aged 21 to 65 years, and (2) triennial cytology for women aged 21 to 29 years followed by cytology plus testing for high-risk human papillomavirus types every 5 years for women aged 30 years and older. Providing women with affordable, easily accessible screening, follow-up of abnormal tests, and timely treatment will result in the greatest impact of screening on cervical cancer incidence and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.